Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia DOI Creative Commons
Snežana Medić, Cleo Anastassopoulou, Zagorka Lozanov-Crvenković

et al.

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(2), P. e2255779 - e2255779

Published: Feb. 13, 2023

During the COVID-19 pandemic, children and adolescents were massively infected worldwide. In 2022, reinfections became a main feature of endemic phase SARS-CoV-2, so it is important to understand epidemiology clinical impact reinfections.To assess incidence, risk, severity pediatric SARS-CoV-2 reinfection.This retrospective cohort study used epidemiologic data documented infections from surveillance database Institute for Public Health Vojvodina. A total 32 524 Vojvodina, Serbia, with laboratory-confirmed infection between March 6, 2020, April 30, followed up reinfection until July 31, 2022.Incidence rates per 1000 person-months, estimated risk 90 days or more after laboratory confirmation primary infection, severity, hospitalizations, deaths.The included (mean [SD] age, 11.2 [4.9] years; 15 953 [49.1%] male), including 964 (3.0%) who experienced reinfection. The incidence rate was 3.2 (95% CI, 3.0-3.4) cases person-months highest in aged 12 17 years (3.4; 95% 3.2-3.7). Most (905 [93.9%]) recorded 2022. cumulative 1.3% at 6 months, 1.9% 9 4.0% 6.7% 7.2% 18 7.9% 21 months. Pediatric generally mild. proportion severe forms decreased 14 (1.4%) initial episodes 3 (0.3%) reinfections. Reinfected approximately 5 times less likely have disease during compared (McNemar odds ratio, 0.2; 0.0-0.8). rarely led hospitalization (0.5% vs infections), none resulted death.This found that remained substantially lower adults as mild, even milder than infections.

Language: Английский

Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines DOI Creative Commons
Alessandro Sette, Shane Crotty

Immunological Reviews, Journal Year: 2022, Volume and Issue: 310(1), P. 27 - 46

Published: June 22, 2022

Immunological memory is the basis of protective immunity provided by vaccines and previous infections. can develop from multiple branches adaptive immune system, including CD4 T cells, CD8 B long-lasting antibody responses. Extraordinary progress has been made in understanding to SARS-CoV-2 infection COVID-19 vaccines, addressing development; quantitative qualitative features different cellular anatomical compartments; durability each component antibodies. Given sophistication measurements; size human studies; use longitudinal samples cross-sectional head-to-head comparisons between or for 1 year already supersedes that any other acute infectious disease. This knowledge may help inform public policies regarding as well scientific development future against diseases.

Language: Английский

Citations

222

Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19 DOI Open Access
Keith Sacco, Riccardo Castagnoli, Svetlana Vakkilainen

et al.

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(5), P. 1050 - 1062

Published: Feb. 17, 2022

Language: Английский

Citations

202

T Cell Responses to SARS-CoV-2 DOI
Alessandro Sette, John Sidney, Shane Crotty

et al.

Annual Review of Immunology, Journal Year: 2023, Volume and Issue: 41(1), P. 343 - 373

Published: Feb. 8, 2023

A large body of evidence generated in the last two and a half years addresses roles T cells SARS-CoV-2 infection following vaccination. Infection or vaccination induces multi-epitope CD4 CD8 cell responses with polyfunctionality. Early have been associated mild COVID-19 outcomes. In concert animal model data, these results suggest that while antibody are key to prevent infection, may also play valuable reducing disease severity controlling infection. memory after is sustained for at least six months. While neutralizing impacted by variants, most preserved. This review highlights extensive progress made, data knowledge gaps remain, our understanding vaccines.

Language: Английский

Citations

131

SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021 DOI Creative Commons
Hannah C. Lewis, Harriet Ware, Mairead Whelan

et al.

BMJ Global Health, Journal Year: 2022, Volume and Issue: 7(8), P. e008793 - e008793

Published: Aug. 1, 2022

Estimating COVID-19 cumulative incidence in Africa remains problematic due to challenges contact tracing, routine surveillance systems and laboratory testing capacities strategies. We undertook a meta-analysis of population-based seroprevalence studies estimate SARS-CoV-2 inform evidence-based decision making on public health social measures (PHSM) vaccine strategy.

Language: Английский

Citations

129

Adaptive Immune Responses and Immunity to SARS-CoV-2 DOI Creative Commons
Dragan Primorac,

Kristijan Vrdoljak,

Petar Brlek

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: May 4, 2022

Since the onset of COVID-19 pandemic, medical field has been forced to apply basic knowledge immunology with most up-to-date SARS-CoV-2 findings and translate it population whole world in record time. Following infection viral antigen, adaptive immune responses are activated mainly by particle encounters antigen-presenting cells or B cell receptors, which induce further biological interactions defend host against virus. After warded off, immunological memory is developed. The SARS-CoV cellular immunity shown persist even 17 years after infection, despite undetectable humoral component. Similar demonstrated for T a shorter period assessing interferon-gamma levels when heparinized blood stimulated virus-specific peptides. also play an irreplaceable part reaction as backbone response. They both provide signals activation maturation, competence, production IgA was be significant influence mediating mucosal first defense mechanism development nasal vaccines. Here, we interpret recent available research, encompasses significance current understanding activity, compare among naive, exposed, vaccinated donors. Our data showed that those who recovered from EMA-approved vaccines had long-lasting immunity. Additionally, analyze immunocompromised patients mediated impact clonality pandemic regarding breakthrough infections variants concern, B.1.617.2 (Delta) B.1.1.529 (Omicron) variants.

Language: Английский

Citations

99

Multisystem Inflammatory Syndrome in Children and Long COVID: The SARS-CoV-2 Viral Superantigen Hypothesis DOI Creative Commons
Magali Noval Rivas, Rebecca A. Porritt, Mary Hongying Cheng

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: July 7, 2022

Multisystem inflammatory syndrome in children (MIS-C) is a febrile pediatric disease that may develop weeks after initial SARS-CoV-2 infection or exposure. MIS-C involves systemic hyperinflammation and multiorgan involvement, including severe cardiovascular, gastrointestinal (GI) neurological symptoms. Some clinical attributes of MIS-C—such as persistent fever, rashes, conjunctivitis oral mucosa changes (red fissured lips strawberry tongue)—overlap with features Kawasaki (KD). In addition, shares striking similarities toxic shock (TSS), which triggered by bacterial superantigens (SAgs). The remarkable between TSS prompted search for SAg-like structures the virus discovery unique motif highly similar to Staphylococcal enterotoxin B (SEB) fragment spike 1 (S1) glycoprotein. Computational studies suggest has high affinity binding T-cell receptors (TCRs) MHC Class II proteins. Immunosequencing peripheral blood samples from patients revealed profound expansion TCR β variable gene 11-2 (TRBV11-2), correlates severity serum cytokine levels, consistent SAg-triggered immune response. sequence analysis further identified conserved neurotoxin-like motifs alter neuronal cell function contribute symptoms COVID-19 patients. Additionally, autoantibodies are detected during MIS-C, indicate development post-SARS-CoV-2 autoreactive autoimmune responses. Finally, prolonged persistence RNA gut, increased gut permeability elevated levels circulating S1 have been observed MIS-C. Accordingly, we hypothesize continuous exposure viral promote autoimmunity leading post-acute syndromes, long COVID, well complications resulting infection.

Language: Английский

Citations

95

Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors DOI Creative Commons
Levente Zsichla, Viktor Müller

Viruses, Journal Year: 2023, Volume and Issue: 15(1), P. 175 - 175

Published: Jan. 7, 2023

The clinical course and outcome of COVID-19 are highly variable, ranging from asymptomatic infections to severe disease death. Understanding the risk factors is relevant both in setting at epidemiological level. Here, we provide an overview host, viral environmental that have been shown or (in some cases) hypothesized be associated with outcomes. considered detail include age frailty, genetic polymorphisms, biological sex (and pregnancy), co- superinfections, non-communicable comorbidities, immunological history, microbiota, lifestyle patient; variation infecting dose; socioeconomic factors; air pollution. For each category, compile (sometimes conflicting) evidence for association factor outcomes (including strength effect) outline possible action mechanisms. We also discuss complex interactions between various factors.

Language: Английский

Citations

74

Identification of a conserved S2 epitope present on spike proteins from all highly pathogenic coronaviruses DOI Creative Commons

Rui P. Silva,

Yimin Huang, Annalee W. Nguyen

et al.

eLife, Journal Year: 2023, Volume and Issue: 12

Published: March 21, 2023

To address the ongoing SARS-CoV-2 pandemic and prepare for future coronavirus outbreaks, understanding protective potential of epitopes conserved across variants lineages is essential. We describe a highly conserved, conformational S2 domain epitope present only in prefusion core β-coronaviruses: apex residues 980–1006 flexible hinge. Antibody RAY53 binds native hinge MERS-CoV spikes on surface mammalian cells mediates antibody-dependent cellular phagocytosis cytotoxicity against spike vitro. Hinge mutations that ablate antibody binding compromise pseudovirus infectivity, but changes elsewhere affect opening dynamics, including those found Omicron BA.1, occlude may evade pre-existing serum antibodies targeting core. This work defines third class while providing insights into potency limitations targeting.

Language: Английский

Citations

67

Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection DOI Creative Commons
Marc Stegger, Sofie Marie Edslev, Raphael N. Sieber

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Feb. 22, 2022

Abstract The newly found Omicron SARS-CoV-2 variant of concern has rapidly spread worldwide. carries numerous mutations in key regions and is associated with increased transmissibility immune escape. recently been divided into four subvariants substantial genomic differences, particular between BA.1 BA.2. With the surge BA.2, a large number reinfections from earlier cases observed, raising question whether BA.2 specifically can escape natural immunity acquired shortly after infection. To investigate this, we selected subset samples more than 1,8 million infections period November 22, 2021, until February 11, 2022. Here, individuals two positive samples, 20 less 60 days apart, were selected. From total 187 reinfection cases, identified 47 instances infection, mostly young unvaccinated mild disease not resulting hospitalization or death. In conclusion, provide evidence that do occur but are rare.

Language: Английский

Citations

70

Pulmonary Dysfunction after Pediatric COVID-19 DOI
R. Heiß,

Lina Tan,

Sandy Schmidt

et al.

Radiology, Journal Year: 2022, Volume and Issue: 306(3)

Published: Sept. 20, 2022

Background Long COVID occurs at a lower frequency in children and adolescents than adults. Morphologic free-breathing phase-resolved functional low-field-strength MRI may help identify persistent pulmonary manifestations after SARS-CoV-2 infection. Purpose To characterize both morphologic changes of lung parenchyma with post–COVID-19 condition compared healthy controls. Materials Methods Between August December 2021, cross-sectional clinical trial using was performed from single academic medical center. The primary outcome the MRI. Secondary outcomes included MRI-derived proton ventilation perfusion parameters. Clinical symptoms, duration positive reverse transcriptase–polymerase chain reaction test result, serologic parameters were imaging results. Nonparametric tests for pairwise corrected groupwise comparisons applied to assess differences controls, recovered participants, those long COVID. Results A total 54 participants COVID-19 infection (mean age, 11 years ± 3 [SD]; 30 boys [56%]) nine controls 10 3; seven [78%]) included: 29 (54%) group had 25 (46%) classified as having on day enrollment. abnormality identified one participant. Both ventilated perfused (ventilation-perfusion [V/Q] match) higher (81% 6.1) (62% 19; P = .006) (60% 20; .003). V/Q match patients time study participation less 180 days (63% .03), 180–360 18; 360 (41% 12; < .001) never-infected 6.1). Conclusion Low-field-strength showed dysfunction who registration no. NCT04990531 © RSNA, 2022 Supplemental material is available this article. See also editorial by Paltiel issue.

Language: Английский

Citations

60